Gilead Sciences, Inc.
GILD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $7,769 | $7,081 | $6,667 | $7,569 |
| % Growth | 9.7% | 6.2% | -11.9% | – |
| Cost of Goods Sold | $1,569 | $1,501 | $1,540 | $1,581 |
| Gross Profit | $6,200 | $5,580 | $5,127 | $5,988 |
| % Margin | 79.8% | 78.8% | 76.9% | 79.1% |
| R&D Expenses | $1,346 | $1,491 | $1,379 | $1,641 |
| G&A Expenses | $0 | $501 | $505 | $992 |
| SG&A Expenses | $1,357 | $1,365 | $1,258 | $1,861 |
| Sales & Mktg Exp. | $0 | $864 | $753 | $869 |
| Other Operating Expenses | $170 | $250 | $253 | $34 |
| Operating Expenses | $2,873 | $3,106 | $2,890 | $3,536 |
| Operating Income | $3,327 | $2,474 | $2,237 | $2,452 |
| % Margin | 42.8% | 34.9% | 33.6% | 32.4% |
| Other Income/Exp. Net | $314 | -$45 | -$588 | -$285 |
| Pre-Tax Income | $3,641 | $2,429 | $1,649 | $2,167 |
| Tax Expense | $589 | $468 | $334 | $385 |
| Net Income | $3,052 | $1,960 | $1,315 | $1,783 |
| % Margin | 39.3% | 27.7% | 19.7% | 23.6% |
| EPS | 2.46 | 1.57 | 1.06 | 1.43 |
| % Growth | 56.7% | 48.1% | -25.9% | – |
| EPS Diluted | 2.43 | 1.56 | 1.04 | 1.42 |
| Weighted Avg Shares Out | 1,243 | 1,245 | 1,246 | 1,248 |
| Weighted Avg Shares Out Dil | 1,254 | 1,255 | 1,259 | 1,259 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $73 | $94 | $85 |
| Interest Expense | $256 | $254 | $260 | $249 |
| Depreciation & Amortization | $686 | $691 | $696 | $693 |
| EBITDA | $4,583 | $3,374 | $2,605 | $3,109 |
| % Margin | 59% | 47.6% | 39.1% | 41.1% |